Pancreatic Cancer Research

ResearcherSamsung Medical CenterActive in the last 2 years

Jin Seok Heo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6767-2790; OpenAlex author ID A5034683497. Sources: OpenAlex.

Their work

Papers
47 (first author 5, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
122
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: none · 2017: 4 papers · 2018: 2 papers · 2019: none · 2020: 5 papers · 2021: 8 papers · 2022: 4 papers · 2023: 7 papers · 2024: 2 papers · 2025: 9 papers · 2026: 3 papers

Papers 47

  1. Prognostic Value of Pseudotime from Texture Parameters of [18F]fluorodeoxyglucose PET/CT in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.acra.2025.10.016↗
  2. Multivisceral resection for pancreatic ductal adenocarcinoma with adjacent organ invasion: a propensity score-matched analysis. Co-author DOI 10.1016/j.gassur.2026.102412↗
  3. Development of an artificial intelligence-based prediction platform for early recurrence of resectable pancreatic cancer after curative surgery-toward future u… Co-author DOI 10.4174/astr.2026.110.2.76↗
  4. Artificial Intelligence-Powered Spatial Analysis of Immune Phenotypes in Resected Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2025.1999↗
  5. Skeletal Muscle Index Changes on Locoregional Treatment Application After FOLFIRINOX and Survival in Pancreatic Cancer. Co-author DOI 10.1002/jcsm.13643↗
  6. Synthetic data generation method improves risk prediction model for early tumor recurrence after surgery in patients with pancreatic cancer. Co-author DOI 10.1038/s41598-025-15800-4↗
  7. Implications of portal vein/superior mesenteric vein involvement in pancreatic cancer: A comprehensive correlation from preoperative radiological assessment to… Co-author DOI 10.1097/js9.0000000000002307↗
  8. The impact of distress at diagnosis in patients with pancreatic cancer undergoing pancreatectomy. Co-author DOI 10.1186/s12885-025-14365-9↗
  9. Prognostic Accuracy of ypTNM Stage in Patients with Pancreatic Cancer in the Era of Modern Neoadjuvant Therapy. Co-author DOI 10.1245/s10434-024-16792-7↗
  10. Optimal Number of Lymph Nodes Retrieved to Lower the Risk of False N0 for Patients with Pancreatic Cancer Undergoing Curative Surgery. Co-author DOI 10.1245/s10434-025-18029-7↗
  11. Impact of portal/superior mesenteric vein abutment angle on prognosis in pancreatic cancer: a single-center retrospective cohort study. Co-author DOI 10.4174/astr.2025.108.4.231↗
  12. Predicting prognosis and optimal timing for surgery using CA 19-9 in patients with pancreatic cancer who underwent FOLFIRINOX-based neoadjuvant therapy: a retr… Co-author DOI 10.4174/astr.2025.109.6.348↗
  13. Impact and optimal timing of local therapy addition in borderline resectable or locally advanced pancreatic cancer after FOLFIRINOX chemotherapy. Co-author DOI 10.1016/j.ctro.2024.100732↗
  14. Prognostic Significance of 18 F-FDG PET/CT Radiomics in Patients With Resectable Pancreatic Ductal Adenocarcinoma Undergoing Curative Surgery. Co-author DOI 10.1097/rlu.0000000000005363↗
  15. Features of T1 pancreatic cancer and validation of the eighth edition AJCC staging system definition using a Korean-Japanese joint cohort and the SEER database. First author DOI 10.1002/jhbp.1316↗
  16. Multi-biomarker panel prediction model for diagnosis of pancreatic cancer. Co-author DOI 10.1002/jhbp.986↗
  17. Use of individualized 3D-printed models of pancreatic cancer to improve surgeons' anatomic understanding and surgical planning. Co-author DOI 10.1007/s00330-023-09756-0↗
  18. Prognosis of pancreaticoduodenectomy in octogenarians for pancreatic ductal adenocarcinoma with propensity score matched analysis. Co-author DOI 10.1111/ans.18679↗
  19. Effects of cancer stigma on quality of life of patients with hepatobiliary and pancreatic cancer. Co-author DOI 10.14701/ahbps.22-084↗
  20. Survival Benefit after Shifting from Upfront Surgery to Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer. Co-author DOI 10.3390/biomedicines11082302↗
  21. 15-Year Experience of Distal Pancreatectomy with Celiac Axis Resection (DP-CAR) for Pancreatic Cancer-A Korean Nationwide Investigation. Co-author DOI 10.3390/cancers15153850↗
  22. Comparison of oncologic outcomes between open and laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma using data from the KOTUS-BP national… First author DOI 10.1016/j.hpb.2022.01.012↗
  23. Development of Nomograms for Predicting Prognosis of Pancreatic Cancer after Pancreatectomy: A Multicenter Study. Co-author DOI 10.3390/biomedicines10061341↗
  24. The Feasibility of Stereotactic Body Proton Beam Therapy for Pancreatic Cancer. Co-author DOI 10.3390/cancers14194556↗
  25. Pathological Response Predicts Survival after Pancreatectomy following Neoadjuvant FOLFIRINOX for Pancreatic Cancer. Co-author DOI 10.3390/cancers15010294↗
  26. Appraisal of 5-year recurrence-free survival after surgery in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/jhbp.815↗
  27. Long-term outcomes following en bloc resection for pancreatic ductal adenocarcinoma of the head with portomesenteric venous invasion. Co-author DOI 10.1016/j.asjsur.2020.07.021↗
  28. Usefulness of artificial intelligence for predicting recurrence following surgery for pancreatic cancer: Retrospective cohort study. Co-author DOI 10.1016/j.ijsu.2021.106050↗
  29. Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer. Co-author DOI 10.1177/17588359211038478↗
  30. Upfront Surgery and Surgery Following Neoadjuvant Treatment of Pancreatic Ductal Adenocarcinoma: A Comparative Analysis of Short-term Postoperative Outcomes. Last author DOI 10.21873/anticanres.15386↗
  31. Diagnostic model for pancreatic cancer using a multi-biomarker panel. Co-author DOI 10.4174/astr.2021.100.3.144↗
  32. CORRIGENDUM: Addition of data source: Diagnostic model for pancreatic cancer using a multi-biomarker panel. Co-author DOI 10.4174/astr.2021.100.4.252↗
  33. Development and External Validation of Survival Prediction Model for Pancreatic Cancer Using Two Nationwide Databases: Surveillance, Epidemiology and End Resul… Co-author DOI 10.5009/gnl20306↗
  34. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions. Co-author DOI 10.1186/s13073-020-00776-9↗
  35. Clinical outcomes of pancreaticoduodenectomy for pancreatic ductal adenocarcinoma depending on preservation or resection of pylorus. Last author DOI 10.14701/ahbps.2020.24.3.269↗
  36. Multi-Biomarker Panel Prediction Model for Diagnosis of Pancreatic Cancer: a retrospective and multi-center cohort study Co-author DOI 10.21203/rs.3.rs-76136/v1↗
  37. Neoadjuvant therapy versus upfront surgery for borderline-resectable pancreatic cancer. Co-author DOI 10.23736/s0026-4733.19.07958-6↗
  38. Predictive Nomogram for Early Recurrence after Pancreatectomy in Resectable Pancreatic Cancer: Risk Classification Using Preoperative Clinicopathologic Factors. Co-author DOI 10.3390/cancers12010137↗
  39. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospect… Co-author DOI 10.1097/sla.0000000000002705↗
  40. Correction: Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel. Co-author DOI 10.18632/oncotarget.24175↗
  41. Actual long-term outcome of T1 and T2 pancreatic ductal adenocarcinoma after surgical resection. First author DOI 10.1016/j.ijsu.2017.02.007↗
  42. Large-scale clinical validation of biomarkers for pancreatic cancer using a mass spectrometry-based proteomics approach. Co-author DOI 10.18632/oncotarget.17463↗
  43. Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel. Co-author DOI 10.18632/oncotarget.21861↗
  44. Extended versus peripancreatic lymph node dissection for the treatment of left-sided pancreatic cancer. First author DOI 10.4174/astr.2017.92.6.411↗
  45. Glucagon/insulin ratio in preoperative screening before pancreatic surgery: correlation with hemoglobin A1C in subjects with and without pancreatic cancer. Co-author DOI 10.1007/s12020-013-0159-9↗
  46. Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/pmic.201200101↗
  47. Factors affecting long-term survival after surgical resection of pancreatic ductal adenocarcinoma. First author DOI 10.4174/jkss.2011.81.6.394↗

Closest collaborators

The 25 strongest of 122 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. In Woong Han · 33 shared papers, 2017–2026 · strength 5.88
  2. Sang Hyun Shin · 25 shared papers, 2020–2026 · strength 4.91
  3. Hongbeom Kim · 20 shared papers, 2020–2026 · strength 3.90
  4. So Jeong Yoon · 16 shared papers, 2021–2026 · strength 3.35
  5. Hochang Chae · 7 shared papers, 2025–2026 · strength 1.83
  6. Hye Jeong Jeong · 8 shared papers, 2022–2025 · strength 1.78
  7. Hyeong Seok Kim · 6 shared papers, 2025 · strength 1.51
  8. Chang Moo Kang · 11 shared papers, 2017–2026 · strength 1.41
  9. Joon Oh Park · 11 shared papers, 2018–2025 · strength 1.26
  10. Jin‐Young Jang · 12 shared papers, 2017–2023 · strength 1.22
  11. Joo Kyung Park · 10 shared papers, 2017–2025 · strength 1.21
  12. Ji Hye Min · 5 shared papers, 2023–2025 · strength 1.03
  13. Ho Kyoung Hwang · 5 shared papers, 2021–2026 · strength 0.91
  14. Jeong Il Yu · 4 shared papers, 2022–2026 · strength 0.85
  15. Kwang Hyuck Lee · 5 shared papers, 2012–2026 · strength 0.84
  16. Seung Hyup Hyun · 3 shared papers, 2024–2026 · strength 0.81
  17. Wooil Kwon · 9 shared papers, 2017–2023 · strength 0.78
  18. Jong Kyun Lee · 5 shared papers, 2017–2025 · strength 0.76
  19. Seungyeoun Lee · 8 shared papers, 2017–2023 · strength 0.72
  20. Taesung Park · 8 shared papers, 2017–2023 · strength 0.72
  21. Song Cheol Kim · 7 shared papers, 2018–2023 · strength 0.70
  22. Kyu Taek Lee · 4 shared papers, 2022–2025 · strength 0.70
  23. Yoo‐Seok Yoon · 5 shared papers, 2021–2023 · strength 0.66
  24. Seong Ho Choi · 8 shared papers, 2012–2021 · strength 0.65
  25. Joon Young Choi · 2 shared papers, 2024–2026 · strength 0.57

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.